3D Global Biotech Inc. (TPEX:6808)
Taiwan · Delayed Price · Currency is TWD 31.30
-0.70 (-2.19%)
Sep 7, 2026, 1:25 PM CST
3D Global Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,463 | 3,760 | 5,131 | 1,088 | 1,498 | 2,143 | |
Market Cap Growth | -37.46% | -26.72% | 371.49% | -27.35% | -30.09% | -18.98% |
Enterprise Value | 2,011 | 3,076 | 4,797 | 915 | 1,295 | 1,901 |
Last Close Price | 32.00 | 48.14 | 65.92 | 18.93 | 26.23 | 38.65 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 174.08 | 56.51 | 55.95 | - | - | - |
PS Ratio | 15.47 | 18.19 | 19.31 | 52.74 | 109.79 | 193.46 |
PB Ratio | 3.36 | 3.82 | 5.67 | 3.71 | 4.40 | 5.50 |
P/TBV Ratio | 3.70 | 4.13 | 6.28 | 5.69 | 6.70 | 9.03 |
P/FCF Ratio | 46.46 | 35.90 | 344.12 | - | - | - |
P/OCF Ratio | 37.37 | 33.90 | 261.08 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 12.64 | 14.88 | 18.05 | 44.33 | 94.89 | 171.68 |
EV/EBITDA Ratio | 107.45 | 52.89 | 45.85 | - | - | - |
EV/EBIT Ratio | - | 74.20 | 54.20 | - | - | - |
EV/FCF Ratio | 37.94 | 29.37 | 321.70 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.05 | 0.09 | 0.04 | 0.05 | 0.06 |
Debt / EBITDA Ratio | 2.41 | 0.71 | 0.77 | - | - | - |
Debt / FCF Ratio | 0.85 | 0.47 | 5.69 | - | - | - |
Net Debt / Equity Ratio | -0.62 | -0.43 | -0.68 | -0.53 | -0.56 | -0.54 |
Net Debt / EBITDA Ratio | -42.53 | -7.37 | -5.92 | 3.35 | 4.07 | 4.99 |
Net Debt / FCF Ratio | -8.52 | -4.09 | -41.52 | 4.81 | 5.43 | 5.45 |
Asset Turnover | 0.17 | 0.19 | 0.39 | 0.06 | 0.03 | 0.02 |
Inventory Turnover | 1.90 | 3.96 | 17.14 | 4.41 | 5.14 | 9.16 |
Quick Ratio | 10.83 | 13.49 | 15.75 | 6.34 | 10.41 | 15.71 |
Current Ratio | 11.61 | 14.08 | 15.93 | 6.63 | 10.71 | 16.04 |
Return on Equity (ROE) | 1.73% | 7.04% | 15.31% | -18.28% | -18.37% | -14.24% |
Return on Assets (ROA) | -0.41% | 2.44% | 8.12% | -11.30% | -10.41% | -8.57% |
Return on Invested Capital (ROIC) | -1.55% | 9.85% | 39.90% | -43.84% | -40.57% | -33.56% |
Return on Capital Employed (ROCE) | -0.80% | 3.90% | 9.00% | -21.10% | -18.90% | -15.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.58% | 1.77% | 1.79% | -5.33% | -4.48% | -2.79% |
FCF Yield | 2.15% | 2.79% | 0.29% | -2.98% | -2.36% | -1.81% |
Dividend Yield | 0.32% | 0.21% | 0.80% | - | - | - |
Payout Ratio | 290.69% | 62.03% | - | - | - | - |
Buyback Yield / Dilution | 0.89% | -11.92% | -26.08% | -2.32% | -1.69% | -0.77% |
Total Shareholder Return | 1.21% | -11.71% | -25.27% | -2.32% | -1.69% | -0.77% |